_the-veldink-family-talks-about-ataxia-telangiectasia-preview-1.jpg "The Veldink Family Talks About Ataxia-Telangiectasia from ataxia telangiectasia Video Screenshot Preview 1")
Gallery_the-veldink-family-talks-about-ataxia-telangiectasia-preview-3.jpg "The Veldink Family Talks About Ataxia-Telangiectasia from ataxia telangiectasia Video Screenshot Preview 3")
Gallery_the-veldink-family-talks-about-ataxia-telangiectasia-preview-hqdefault.jpg "The Veldink Family Talks About Ataxia-Telangiectasia from ataxia telangiectasia Video Screenshot Preview hqdefault")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Jump To Video Parts
⏲ Duration: 10 minutes 42 seconds
👁 View: 3.5K times
Play Audio:👁 View: 3.5K times
Description:
Andy Phelps
Andy Phelps
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_faces-of-a-t-ataxia-telangiectasia-2010-neuro-film-festival.webp "curetour")
_ataxia-telangiectasia-immunology-usmle-step-1.webp "LearnToBetterLife")
_aiarako-maratoi-solidarioa-maratn-solidario-de-ayala.webp "Ataxia telangiektasiaren ikerketaren alde; sendabiderik eta tratamendurik gabeko gaitz arraro eta neurodegeneratiboa duten hiru gaixo dude Euskadin.nA beneficio de la investigación de la ataxia telangiectasia, enfermedad rara y neurodegenerativa, sin cura ni tratamiento, que afecta a tres chicos en Euskadi.")
_ataxia-telangiectasia.webp "USMLEQA formerly USMLEFastTrack")
_matinntak-og-ernringsstatus-ved-ataxia-telangiectasia.webp "Gro Trae, klinisk ernæringsfysiolog, FrambunFra kurs på Frambu 24. februar 2016")
_national-ataxia-telangiectasia-a-t-clinic-ten-news-segment.webp "Wesley Research Institute")
_ataxia-telangiectasia-rapid-review-primary-immunodeficiencies-chapter-of-the-achiever39s-course.webp "The Achiever's Edge By Dr Sandeep Sharma")
⏲ 4 minutes 51 seconds 👁 1.2K
_safety-and-efficacy-of-the-oral-atr-inhibitor-elimusertib-in-advanced-solid-tumours-with-dna-damage-response-defects.webp "Dr Timothy Yap speaks to ecancer as part of the AACR 2022 meeting about a study evaluating the safety and efficacy of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor elimusertib in advanced solid tumours with DNA damage response defects.nnHe reports that clinical benefit with disease control for at least 16 weeks was achieved in at least 35% of patients treated with elimusertib and that durable responses were seen over a variety of cancer types. nnDr Yap also explains that the ad")
⏲ 2 min 49 sec ✓ 11-Apr-2022
_faces-of-a-t-ataxia-telangiectasia-2010-neuro-film-festival.jpg)
_ataxia-telangiectasia-immunology-usmle-step-1.jpg)
_aiarako-maratoi-solidarioa-maratn-solidario-de-ayala.jpg)
_ataxia-telangiectasia.jpg)
_matinntak-og-ernringsstatus-ved-ataxia-telangiectasia.jpg)
_national-ataxia-telangiectasia-a-t-clinic-ten-news-segment.jpg)
_ataxia-telangiectasia-rapid-review-primary-immunodeficiencies-chapter-of-the-achiever39s-course.jpg)
_safety-and-efficacy-of-the-oral-atr-inhibitor-elimusertib-in-advanced-solid-tumours-with-dna-damage-response-defects.jpg)
![[+]](/images/menu.gif){kind=small}